Oncotype DX breast CPT 81519 in accordance with the established GSA schedule #V979D-70053
Ended Awarded Last action
- Contract number
- HT001425FE002
- Awardee
-
Exact Sciences Corporation UEI NGBXEJX5GLE9
- Awarding agency
-
Defense Health Agency
Department of Defense
- Obligated
- $86,349
Award facts
- Contract value 11% obligated
-
- $86,349.00 Current, with exercised options
- $777,141.00 Potential, with all options
- Completion date 100% complete
-
- Current, with exercised options
- Potential, with all options
- Contracting staff
- NAICS code
- 621511 Medical Laboratories
- PSC
- Q301 Reference Laboratory Testing
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 1 offer Multiple Award, Fair Opportunity
- Pricing
- Firm Fixed Price
- Place of performance
- Fort Belvoir, VA 22060, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | $0 | |
| Original award | $86,349 |
About this award
The Defense Health Agency has awarded a delivery order valued at $777,141 to Exact Sciences Corporation for Oncotype DX Breast CPT 81519 testing services, with performance scheduled through February 11, 2030. This contract was awarded under the GSA Schedule Medical Laboratory Testing and Analysis Services (FSS-621-II) without a set-aside designation, reflecting Exact Sciences' competitive positioning as a specialized provider of genomic diagnostic testing. The work will be performed at Fort Belvoir, Virginia, and represents a firm fixed-price engagement for advanced diagnostic testing services supporting the Defense Health Agency's cancer screening and personalized medicine initiatives.
This delivery order is part of Exact Sciences Laboratories, LLC's broader portfolio of federal contracts providing oncology testing services across the Department of Defense and Veterans Affairs healthcare systems. The company has established itself as a key provider of gene expression profiling and genomic assays, with existing blanket purchase agreements and indefinite delivery vehicles across multiple federal agencies. The Oncotype DX breast cancer genomic assay is a recognized clinical tool for assessing breast cancer recurrence risk and informing treatment decisions, making it a critical diagnostic capability for military beneficiaries receiving care through Defense Health Agency facilities.
Quick answers
Who was awarded contract HT001425FE002?
HT001425FE002 was awarded to Exact Sciences Corporation by Defense Health Agency (Department of Defense) on August 12, 2025.
How much is contract HT001425FE002 worth?
The government has obligated $86,349 on HT001425FE002. Its potential value, with all options, is $777,141.
Is contract HT001425FE002 an order under another contract?
Yes. HT001425FE002 is a delivery order under V797D70053, a federal supply schedule, on Medical Laboratory Testing and Analysis Services (FSS-621-II).
Was contract HT001425FE002 competed?
The extent of competition for HT001425FE002 was full and open competition. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award